

Sera Kim, CFA skim@gmpsecurities.com (416) 943-6639 Associate: Chris Lee clee@gmpsecurities.com (416) 943-6664

At the Opening March 24, 2008

Intrinsyc Software Inc.^{1,7} ICS C\$0.75

BUY Target: C\$1.50

What's Changed				
		New	Old	
Recommendation		n/c	BUY	
Target		n/c	C\$1.50	
Revenue 2007A (mm)		n/c	C\$19.7	
Revenue 2008E (mm)		n/c	\$22.3	
Revenue 2009E (mm)		n/c	\$43.4	
EPS 2007A		n/c	C(\$0.18)	
EPS 2008E		n/c	(\$0.11)	
EPS 2009E		n/c	(\$0.01)	
Share Data				
Shares – mm (basic/f.d.)*		1	152.3/152.3	
52-week high/low		C\$1	C\$1.30/C\$0.39	
Market capitalization (mm)			C\$114	
Enterprise value (mm)			C\$70	
Net cash (mm)*			C\$44.5	
Total projected return			100%	
Financial Data				
YE Dec. 31	07A	08E	09E	
Revenue (mm)	C\$19.7	\$22.3	\$43.4	
EV/Revenue	3.5x	3.1x	1.6x	
EPS	(C\$0.18)	(\$0.11)	(\$0.01)	
P/E	nm	nm	nm	
EBITDA (mm)	(C\$14.2)	(\$15.9)	(\$0.9)	
All figures in US\$, unless otherwise stated				

Transition period results in line; Soleus on track for royalty revenues in 2H08

- Rev \$5.2 mm (as expected), and net loss \$7.3 mm (vs. our \$6.8 mm loss estimate)
- Investors should focus on Soleus, which should start to make an impact on revenues and gross margins in 2H/08 and beyond as royalty revenues start to ramp
- All Soleus customers are progressing well and tracking to plan, in our view
- We continue to expect at least one new design win per quarter to maintain the positive momentum
- No changes to our forecast; reiterate BUY rating

NO MAJOR SURPRISES TO STUB PERIOD RESULTS

Note: F07 in C\$ with Aug YE; all others reflect Dec YE

*reflects impact of recent equity financing

For the four-month period, revenues of \$5.2 million matched our estimate. On the bottom line, net losses amounted to \$7.2, compared to our \$6.8 million loss estimate. Net losses include a \$0.7 million charge related to a previously announced restructuring to close the UK operations. The variance relative to our net loss estimate is primarily attributed to lower-than-expected gross margins of 36.4% (vs. our 40.7% estimate). We had already factored in a decline in gross margins to reflect lower-margin services business for three Soleus customers. However, the company had a further impact due to the weaker US\$ relative to the C\$, and a delay in signing an Engineering Services contract during the transition period (which has since been signed).

SOLEUS IS PROGRESSING WELL AND TRACKING TO PLAN, IN OUR VIEW

Recall, the key to our investment thesis is Soleus, and the company's successful transition from an Engineering Services business to a more attractive royalty-based software business model with Soleus. During the transition period, Soleus revenue was still immaterial at only \$140K reflecting upfront licensing and maintenance fees from announced design wins. Based on the comments during the call, we remain confident that Soleus is tracking to plan. Management indicated that MSI's 5608 device is currently in field trials, and initial shipments of Soleus-based devices are expected to start late in Q2/08. This is exactly in line with our forecast model.

See important disclosures at end of this report.



Sera Kim, CFA skim@gmpsecurities.com (416) 943-6639 Associate: Chris Lee clee@gmpsecurities.com (416) 943-6664

In addition to existing design wins, Intrinsyc continues to have active discussions with potential customers for future Soleus wins. We continue to expect multiple design wins with existing customers, similar to Mitac, and intentions from MSI to launch additional devices based on the Soleus platform. In addition, we believe Intrinsyc has made a positive impact on its initial Soleus customers as evidenced by their willingness to introduce Intrinsyc to other departments and deepen the business relationships (increasing the potential for additional design wins). Future versions of the platform (i.e., 3G, enhanced user interface) will continue to add value to customers.

NO CHANGES TO OUR FORECAST, REITERATE BUY RATING AND C\$1.50 TARGET

Our outlook

Q1/08E: We expect revenue of \$5.0 million and net loss of \$4.4 million, or (\$0.03) per share. In Q1/08, we expect Soleus revenue to be immaterial again as Soleus-based devices will not start shipping until late Q2/08.

F2008E: We expect revenue of \$22.3 million and net loss of \$16.3 million, or (\$0.11) per share. In F2008, we expect Soleus to contribute \$3.0 million.

F2009E: We expect revenue of \$43.4 million and net loss of \$1.5 million, or (\$0.01) per share. Soleus revenue is expected to contribute \$23 million in F2009. We expect the company to be profitable by Q4/09.

F2010E: We expect revenue of \$60.0 million and net income of \$6.7 million, or \$0.04 per share. Soleus revenue is expected to contribute \$38 million to overall sales in F2010.

RECOMMENDATION

We continue to believe Intrinsyc is an exciting story with significant upside potential for growth-oriented investors. The company is led by a strong management team that has proven its ability to execute. Intrinsyc is at the cusp of finally reaping the rewards of transitioning from an engineering services business to a more attractive royalty-based software business model, which comes with more scalability, higher margins and greater predictability of revenue streams. The success of Soleus is key to the story. Intrinsyc has an impressive pace of design wins to date, which speaks to Soleus' ability to address the critical needs of a large and growing market for consumer-oriented feature phones and converged mobile devices.

We reiterate our BUY rating and C\$1.50 target price on Intrinsyc. Our target price implies a C2009 EV/S multiple of 4.2x and is supported by a sum-of-the-parts analysis (valuing Soleus and the Engineering Services business separately) and a DCF valuation. At current levels, the shares are attractively valued, trading at a C2009 EV/S of 1.6x, a discount to the group average of 2.7x. We believe a premium multiple for Intrinsyc is justified given the strong expected growth as Soleus revenues ramp up. We are projecting Intrinsyc's 2009/2008 sales to grow 95%, compared to the group average of 23%.



Sera Kim, CFA skim@gmpsecurities.com (416) 943-6639 Associate: Chris Lee clee@gmpsecurities.com (416) 943-6664

¹ GMP Securities L.P. has, within the previous 12 months, provided paid investment banking services or acted as underwriter to the issuer. ² GMP Securities L.P. is a market maker for the securities of the issuer.

³ non-voting

⁴ subordinate-voting

⁵ restricted-voting

⁶ multiple-voting

⁷ The analyst who prepared this report has viewed the material operations of this issuer.

⁸ The analyst who prepared this research report owns this issuer's securities.

9 limited voting

¹⁰ GMP Securities L.P. owns 1% or more of this issuer's securities.

The information contained in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does GMP Securities L.P. ("GMP") assume any responsibility or liability whatsoever. Information on which this report is based is available upon request. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. GMP and/or affiliated companies or persons may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or other derivative instruments thereon and may, as principal or agent, buy and sell such products. Griffiths McBurney Corp., an affiliate of GMP, accepts responsibility for the contents of this research subject to the foregoing. U.S. clients wishing to effect transactions in any security referred to herein should do so through Griffiths McBurney Corp. GMP will provide upon request a statement of its financial condition and a list of the names of its directors and senior officers. © GMP. All rights reserved. Reproduction in whole or in part without permission is prohibited. 145 King Street West, Suite 300 Toronto, Ontario M5H 1J8 Tel: (416) 367-8600; Fax: (416) 943-6134.

Each research analyst and associate research analyst who authored this document and whose name appears herein certifies that (1) the recommendations and opinions expressed in the research report accurately reflect their personal views about any and all of the securities or issuers discussed herein that are within their coverage universe and (2) no part of their compensation was, is or will be, directly or indirectly, related to the provision of specific recommendations or views expressed herein.

GMP Analysts are compensated competitively based on several criteria, including performance assessment criteria based on quality of research. The Analyst compensation pool is comprised of several revenue sources, including, sales and trading and investment banking.

GMP policies do not allow the issuer to pay any expenses associated with a visit to its material operations by the Analyst.

GMP Securities L.P. prohibits any director, officer, employee or Canadian agent of GMP from holding any office in publicly traded companies or any office in private companies in the financial services industry.

All relevant disclosures required by Policy 11 may be obtained by calling your Investment Advisor. GMP's recommendation statistics and research dissemination policies can be obtained at www.gmpsecurities.com or by calling your investment advisor.

The GMP research recommendation structure consists of the following categories:

FOCUS BUY. Small cap stocks (defined as stocks with less than \$500 million market capitalization) in this category have a total return potential (including dividends payable) of greater than 25% and large cap stocks a greater than 20% total return potential, as well as superior qualitative and timing characteristics. BUY. These stocks will have 15% or greater (small cap) or 10% or greater (large cap) total return potential.

HOLD. Small cap stocks ranked Hold will have a total return potential of 0% to 15%; large cap stocks ranked Hold will have a total return potential of 0 to 10%. REDUCE. Companies ranked Reduce have a negative potential total return.

FOCUS REDUCE. Companies ranked Focus Reduce have a significant negative potential total return and materially compromised qualitative and timing characteristics.

Note: Analysts have discretion within 500 basis points of the upper and lower limit of each rating to maintain the recommendation.